Abbott Files for Registration of Innovative Formulation for the ...
With this novel, breakthrough technology, the more convenient lopinavir/ ritonavir tablet formulation will allow adult patients to take fewer pills with
or ...
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/P...
|
Research & Development - Departments - Pharmaceutics
Torrent's Novel Drug Delivery research is focused on the development of innovative new ... Dispersible Formulations :. Amoxycillin Dispersible 125mg
Tablet ...
http://www.torrentpharma.com/dept_pharmaceutics.php...
|
Abbott Prepares to Submit Heat-Stable Norvir® Tablet for ...
29 Jul 2008 ... Abbott Park, Illinois — Abbott (NYSE: ABT) has announced it will submit registration applications for a novel tablet formulation of its ...
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/P...
|
Pharmacokinetics of a novel diltiazem HCl extended...[J Clin ...
Department of Pharmacokinetics and Toxicology, Biovail Technologies, Ltd., ... A novel diltiazem HCl extended-release (ER) tablet formulation was developed ...
http://www.ncbi.nlm.nih.gov/pubmed/14517197...
|
Abbott Opens New Research Facility and Pilot Plant in Ludwigshafen ...
9 Oct 2008 ... Using the Meltrex™ technology, Abbott developed a new tablet formulation of its leading protease inhibitor lopinavir/ritonavir (known as ...
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/P...
|
{1} And {2} Announce A Development Collaboration For Trigen's ...
Trigen previously announced the successful completion of a Phase I dose escalation study on TGN 167 using a classical rapid release tablet formulation.
...
http://www.biospace.com/news_story.aspx?NewsEntityId=1824532...
|
Abbott Statement on Advancing Pediatric HIV Treatment in ...
Abbott is developing a lower-dose pediatric tablet formulation of its HIV protease inhibitor (PI), lopinavir/ritonavir. Using a novel technology called
...
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/P...
|
Novel Formulation Increases Efficacy of Mesalamine for Treating UC
MMX mesalamine is a novel, high-strength formulation of 5-aminosalicylic acid ( mesalamine, 1.2 g per tablet) using the MMX technology to release ...
http://www.medscape.com/viewarticle/552322...
|
Chronic non-cancer pain: Focus on once-daily tramadol formulations
Recently, a novel technology has been used by Labopharm Inc. (Canada) to ..... Efficacy and safety assessment of a novel once-daily tablet formulation of ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=23...
|
Granulation
Use of a Novel Foam Granulation Technique to Incorporate Low Drug Loading into Immediate Release Tablet Formulations (758 KB PDF). pdf icon Foam Technology:
...
http://www.dow.com/dowexcipients/resources/application/app_g...
|
